Erik Harris
RezoluteAbout Erik Harris
Erik Harris, age 55, joined Rezolute’s Board on March 25, 2025. He is EVP and Chief Commercial Officer at Ultragenyx Pharmaceutical (since June 2019), with prior commercial leadership roles at Crescendo Bioscience, InterMune, Elan, Genentech, and Bristol-Myers Squibb; he began his career as a U.S. Navy Lieutenant Commander and Congressional Fellow. He holds an MBA from Wharton and a B.S. from the U.S. Naval Academy .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Ultragenyx Pharmaceutical (NASDAQ: RARE) | EVP & Chief Commercial Officer | Jun 2019–present; previously SVP & Head of North American Commercial Ops (Jul 2017–Jun 2019) | Led commercial functions for rare-disease portfolio |
| Crescendo Bioscience | Vice President of Commercial | ~6 years (prior to 2017) | Molecular diagnostics commercialization |
| InterMune; Elan; Genentech; Bristol-Myers Squibb | Commercial and marketing roles | Earlier career (dates not specified) | Biopharma commercial leadership |
| U.S. Navy | Lieutenant Commander; Congressional Fellow | Start of career | Leadership and policy experience |
External Roles
| Organization | Role | Event/Start Date | Notes |
|---|---|---|---|
| Inozyme Pharma (NASDAQ: INZY) | Director | Form 3 event date Oct 3, 2024; filed Oct 7, 2024 | Initial statement filed as Director; “No securities are beneficially owned.” |
| Denali Therapeutics (NASDAQ: DNLI) | Director | Form 3 event date Feb 3, 2022; filed Feb 7, 2022 (amended Feb 14, 2022) | Initial statement filed as Director; “No securities are beneficially owned.” |
| Ultragenyx Pharmaceutical (NASDAQ: RARE) | EVP & Chief Commercial Officer (officer) | Form 3 filed Jun 21, 2019 | Disclosed officer status and option/RSU holdings (historical) |
Board Governance
- Independence: The Board determined Mr. Harris to be an independent director under Nasdaq Rule 5605(a)(2) as of June 30, 2025 .
- Committee assignments:
- As of June 30, 2025: Harris had just joined the Board; committee roster showed other members (no Harris listed yet) .
- Effective July 1, 2025: Member, Compensation Committee (Chair: W. Hogenhuis); not on Audit or Nominating .
- Attendance: The Board met 4 times in FY ended June 30, 2025; each director attended at least 75% of Board and committee meetings on which they served .
- Lead independent director/executive sessions: Not disclosed; current Acting Chair is CEO Nevan Elam .
Fixed Compensation (Director)
| Fiscal Year | Component | Amount (USD) |
|---|---|---|
| FY ended Jun 30, 2025 | Board cash retainer | $11,250 |
| FY ended Jun 30, 2025 | Committee fees | $0 (no committee service reflected for FY25) |
Notes:
- Standard committee fee levels disclosed (for other directors): Audit member $10,000; Compensation member $7,000; Nominating member $7,000; Committee chair levels vary (e.g., Compensation Chair $11,000; Audit Chair $15,000; Nominating Chair $11,000) .
Performance Compensation (Director)
| Grant Date | Award Type | Shares | Grant-Date Fair Value (USD) | Exercise Price | Expiration | Vesting Schedule |
|---|---|---|---|---|---|---|
| Mar 25, 2025 | Stock option | 60,000 | $125,670 | $2.89 | 10 years | Vests ratably over 36 months until Mar 24, 2028 |
| FY ended Jun 30, 2025 | RSUs | — | No RSUs granted to Harris in FY25 | — | — | — |
Performance metrics:
- The proxy describes director equity awards with time-based vesting; no performance-based metrics are disclosed for director equity grants in FY25 .
Other Directorships & Interlocks
| Company | Relationship to Rezolute | Interlock/Conflict Considerations |
|---|---|---|
| Ultragenyx (RARE) | Harris is current EVP & CCO; Rezolute directors include former Ultragenyx COO (W. Hogenhuis) | Potential industry overlap in rare diseases; no related-party transactions with Ultragenyx disclosed |
| Inozyme (INZY); Denali (DNLI) | Harris serves/served as director | Broad biotech network; no RZLT-related transactions disclosed |
Expertise & Qualifications
- Commercial leadership across rare disease and specialty pharma; deep market access and launch experience .
- Education: MBA (Wharton), B.S. (U.S. Naval Academy) .
- Military leadership background (Lieutenant Commander; Congressional Fellow) .
Equity Ownership
| Item | Amount | Notes |
|---|---|---|
| Beneficial ownership (Record Date Sep 22, 2025) | 11,666 shares (options exercisable within 60 days) | “Less than 1%” of class (footnote 5) |
| Director options outstanding (Jun 30, 2025) | Vested: 5,000 | Harris |
| Director options outstanding (Jun 30, 2025) | Unvested: 55,000 | Harris |
| Shares pledged/hedged | Prohibited by policy (pledging only with Audit Committee pre-approval) | Insider trading policy restricts short sales, hedging, pledging/margin accounts |
Insider filings and alignment:
- Form 3 filed for RZLT on Mar 26, 2025 indicating “No securities are beneficially owned” at appointment .
- Company has a clawback policy compliant with SEC/Nasdaq for incentive-based compensation recovery on restatements .
Governance Assessment
- Independence and committee role: Independent; placed on Compensation Committee effective July 1, 2025—supports board oversight of pay practices .
- Attendance: At least minimum threshold across Board/committees in FY25 for all directors; Harris joined late in FY and is not singled out for any lapses .
- Ownership alignment: Minimal current beneficial ownership (<1%) with significant unvested options; no RSUs in FY25; time-based vesting aligns retention but lacks performance linkage—neutral to modest alignment signal .
- Conflicts/related-party exposure: No disclosed related-party transactions involving Harris; potential industry interlock via Ultragenyx, but Audit Committee reviews RPTs and none are reported—monitor but no current red flag .
- Policy strength: Prohibitions on hedging/pledging and an adopted clawback policy enhance investor protections .
Appendix: Reference Tables from Proxy
| Board Committees (Effective Jul 1, 2025) | Members |
|---|---|
| Audit | G. Labrucherie (Chair); P. Fauchet; W. Hogenhuis |
| Compensation | W. Hogenhuis (Chair); Erik Harris; N. Kreher |
| Nominating & Governance | N. Kreher (Chair); G. Labrucherie; P. Fauchet |
| Director Cash Fees (FY ended Jun 30, 2025) | Amount (USD) |
|---|---|
| Erik Harris | $11,250 (Board retainer only) |
| Non-Employee Director Options (as of Jun 30, 2025) | Stock Awards Outstanding (Unvested) | Options Outstanding (Vested) | Options Outstanding (Unvested) |
|---|---|---|---|
| Erik Harris | — | 5,000 | 55,000 |
| Beneficial Ownership (Record Date Sep 22, 2025) | Shares | Percent of Class |
|---|---|---|
| Erik Harris (Director) | 11,666 (options exercisable within 60 days) | * (<1%) |
Quotes and disclosures:
- “Mr. Harris was appointed to serve as a member of our Board of Directors on March 25, 2025.”
- “We have determined that as of June 30, 2025… Harris… [is an] independent director[] as defined by Nasdaq Rule 5605(a)(2)” .
- “Our Board held four meetings during the fiscal year ended June 30, 2025. Each of our directors attended at least 75%…” .
- “Insider trading policy prohibits… short sales, options trading, and hedging… and generally prohibits pledging…” .
- “Clawback Policy… recovery of certain incentive-based compensation… up to three years prior…” .
Potential RED FLAGS to monitor:
- Low direct stock ownership relative to options may temper alignment; track future equity accumulation .
- Industry interlock with Ultragenyx in rare disease space; monitor any business interactions or competitive overlaps; none disclosed currently .
- No performance-based criteria attached to director equity awards in FY25; consider evolving best practices for performance-linked director equity .